About VeraDermics
VeraDermics is a publicly listed company based in San Antonio (United States) founded in 2020 by Kyle Ryder. Drug-delivery platforms for pediatric wart treatments are developed. VeraDermics has raised $262.71 million across 5 funding rounds from investors including Marshall Wace, Citadel and Columbia Threadneedle Investments. Its website veradermics.com draws about 14 thousand monthly visits. VeraDermics offers products and services including VDPHL and Dermatology Pipeline. Its focus areas include Life Sciences, Pediatrics, Drugs and Drug Delivery. Its legal entity is Veradermics, Inc. Its competitors include Ironwood Pharma, scPharmaceuticals and Valeritas; 3 of its 3 listed competitors have raised funding.
Company details
VeraDermics was founded in 2020 and is based in San Antonio, United States. Operations focus on the biotechnology sector, where drug-delivery solutions for pediatric dermatological conditions, particularly warts, are developed. The proprietary WartPatch serves as a targeted platform for administering treatments to children, addressing common skin issues in this demographic. Activities emphasize safe and effective delivery mechanisms for young patients.
- Headquarters San Antonio, United States
- Founders Kyle Ryder
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website veradermics.com
- Social LinkedIn X
- Legal Name Veradermics, Incorporated
- Total Equity Funding$262.71M (USD)
in 5 rounds
- Latest Funding Round$150M (USD), Series C
Oct 2025
- InvestorsMarshall Wace
& 16 more
Products & Services of VeraDermics
VeraDermics offers a comprehensive portfolio of products and services, including VDPHL and Dermatology Pipeline.
Once-daily oral treatment for pattern hair loss.
Novel therapeutics for conditions like warts and atopic dermatitis.
Funding Insights of VeraDermics
VeraDermics has successfully raised a total of $262.71M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $150 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $262.71M
- Total Rounds 5
- Last Round Series C — $150M
- First Round $476,100
(Oct 2020)
- Investors Count 17
All 5 funding rounds of VeraDermics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $150M | Series C | – | SR One | |
| Dec 2024 | $75M | Series B | – | Suvretta Capital Management | |
| May 2023 | $15M | Series B | – | – | – |
| Sep 2021 | $22.24M | Series A | – | Prospect Hill Growth Partners, Connecticut Innovations | – |
| Oct 2020 | $476,100 | Seed | – | – | – |
17 investors in total: 16 institutional and 1 angel.
Investors in VeraDermics
VeraDermics has secured backing from 17 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Marshall Wace, Citadel and Columbia Threadneedle Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
PhiFund Ventures is focused on early-stage life sciences investments. | 2021 | phifundvc.com | ||
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
Limited information is provided about the company's activities. | prospecthillgrowth.com | |||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Healthcare startups are funded by this corporate-backed venture capital entity. | lifesciventure.com | New York, United States | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States |
Investor details for VeraDermics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VeraDermics
7 people are tracked at VeraDermics (4 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Kyle Ryder | Founder | Leadership |
Michael Smolinski | Vice President of Development and Scientific Operations | Leadership |
Reid Waldman | Chief Executive Officer | Leadership |
Dominic Carrano | Chief Financial Officer | Leadership |
John Norton | Investor Relations And Corporate Project Manager | Team |
Jessica Bruno | QA Manager | Team |
Erika Sipperly | Controller | Team |
Complete people profiles for VeraDermics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of VeraDermics
VeraDermics is a publicly listed company on the NYSE with ticker symbol MANE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Feb 2026
- Listed onNYSE: MANE
- Listed entityVeradermics, Incorporated
- Exchange sectorHealth technology
- ISINUS9229671048
- Share price$116.26 (-5.02% on the day) · 2026-10-13
- Market capitalisation$4.86B
- Volume (last session)845,106
Timeline of VeraDermics
4 dated milestones of VeraDermics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded VeraDermics is founded.
- Funding First funding round of $476K.
- Funding Latest funding round, Series C, of $150.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of VeraDermics
VeraDermics has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, scPharmaceuticals and Valeritas.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| scpharmaceuticals.com | 2013 | Lexington, United States | $78.75M | 96 | Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure | |
| valeritas.com | 2003 | Bridgewater, United States | $181.36M | 141 | Wearable insulin patch pumps are developed for transdermal delivery. |
Detailed competitors of VeraDermics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of VeraDermics
The website of VeraDermics (veradermics.com) receives about 14.3K visits a month.
- Monthly visits14.3K
▼ 23.1% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as VeraDermics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Veradermics
Complete news archive for VeraDermics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VeraDermics
VeraDermics was founded in 2020.
VeraDermics is headquartered in San Antonio, United States. It is registered at San Antonio, Texas, United States.
VeraDermics is a funded company, having raised a total of $262.71M across 5 funding rounds to date. The company's 1st funding round was a Seed of $476.1K, raised on Oct 2020.
VeraDermics was founded in 2020 and is based in San Antonio, United States. Operations focus on the biotechnology sector, where drug-delivery solutions for pediatric dermatological conditions, particularly warts, are developed. The proprietary WartPatch serves as a targeted platform for administering treatments to children, addressing common skin issues in this demographic. Activities emphasize safe and effective delivery mechanisms for young patients.
VeraDermics's top competitors include Ironwood Pharma, scPharmaceuticals and Valeritas.
VeraDermics offers VDPHL and Dermatology Pipeline.
Yes, VeraDermics is publicly traded on NYSE under the ticker symbol MANE.
VeraDermics has 17 investors. Key investors include Marshall Wace, Citadel, Columbia Threadneedle Investments, Suvretta Capital Management, and Longitude Capital.
VeraDermics operates through Veradermics, Inc..